close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

4.310 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2
...
17 18 19 20 21 22 23 24 Next >
News headline image
Analyst Ratings for Iovance Biotherapeutics ↗
 
Via Benzinga
News headline image
Recap: Iovance Biotherapeutics Q1 Earnings ↗
 
Via Benzinga
News headline image
Iovance Biotherapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, May 9, 2023
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Why Shares of Iovance Biotherapeutics Jumped Monday ↗
The stock bounced back big from its 52-week low last week. 
Via The Motley Fool
News headline image
Wall Street Thinks These 2 Nasdaq Stocks Could Go Parabolic Soon ↗
These two biotech stocks might be significantly undervalued. 
Via The Motley Fool
News headline image
Analyst Expectations for Iovance Biotherapeutics's Future ↗
 
Via Benzinga
News headline image
Expert Ratings for Iovance Biotherapeutics ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Iovance Biotherapeutics ↗
 
Via Benzinga
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Why Shares of Iovance Biotherapeutics Jumped Monday ↗
The company filed a Biologics License Application to the FDA for its lead therapy. 
Via The Motley Fool
News headline image
Why Iovance Biotherapeutics Shares Are Trading Higher Today ↗
Iovance Biotherapeutics (NASDAQ: IOVA) shares are trading higher on Monday after the company completed its Biologics License Application submission for lifileucel. 
Via Benzinga
News headline image
Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider. 
Via Benzinga
What 6 Analyst Ratings Have To Say About Iovance Biotherapeutics ↗
 
Via Benzinga
News headline image
Why Motorsport Games Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket ↗
Gainers Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) shares rose 38.5% to $2.05 in pre-market trading after gaining 8% on Friday. 
Via Benzinga
News headline image
First Republic Bank, KeyCorp And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
News headline image
Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
First TIL Therapy BLA Submission to U.S. Food and Drug Administration 
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
First Biologics License Application (BLA) Submission on Track to Complete in 1Q23 
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023 ↗
 
Via Benzinga
News headline image
American Express, Visa And Other Big Stocks Moving Higher In Friday's Pre-Market Session ↗
U.S. stock futures traded slightly lower this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
News headline image
Why Iovance Biotherapeutics Stock Soared 12% Higher Today ↗
A business, clinical, and regulatory update lifted the spirits of investors. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Acquires Clinigen's IL-2 Product For Upfront £166.7M ↗
 
Via Benzinga
News headline image
Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Why Is Iovance Biotherapeutics (IOVA) Stock Soaring 20% Today? ↗
Although Iovance Biotherapeutics cuts a speculative figure, IOVA stock managed to skyrocket on Monday off insider buying. 
Via InvestorPlace
News headline image
Why Iovance Biotherapeutics Shares Are Trading Higher By Around 19%? Here Are 40 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Winc, Inc. (NYSE: WBEV) rose 88.5% to $0.3901 after dropping over 23% on Friday. Winc, last month, posted a Q3 loss of $0.33 per share. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
US Stocks Start Week On Lower Note; Dow Tumbles 250 Points ↗
U.S. stocks traded lower this morning, with the Dow Jones falling around 250 points on Monday. 
Via Benzinga
News headline image
Iovance Biotherapeutics Stock Is Surging: Here's Why ↗
Iovance Biotherapeutics Inc (NASDAQ: IOVA) shares are trading higher Monday following recent insider buying from Director Wayne Rothbaum. 
Via Benzinga
< Previous 1 2
...
17 18 19 20 21 22 23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today